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ABSTRACT
Major depression is a common problem in adolescents.

Unfortunately, one the most effective antidepressants in
adults, the selective serotonin reuptake inhibitor (SSRI)

paroxetine, is not clinically effective in pediatric
populations. Moreover, this compound can also increase
rates of suicidal ideation and behavior. In contrast, the

SSRI fluoxetine is an effective treatment for depression

in adolescents and has a much lower risk for inducing
suicidal ideation. The mechanism for the paradoxical

increase in suicidal ideation after paroxetine treatment
is unknown and limited research has been done on this

topic. Thus, the goal of the present investigation was to

compare the effects of paroxetine and fluoxetine in
adolescent rats on markers associated with depression and
suicidal behavior in humans. To this end, adolescent male
and female rats were pre-treated with vehicle, paroxetine

(2.5 or 10 mg/kg, IP), or fluoxetine (10 mg/kg, IP) for
ten consecutive days starting on PD 35. The effects of

fluoxetine and paroxetine on reactivity to rewarding
stimuli and anxiety were assessed using sucrose preference
and the elevated plus maze task, respectively. A separate
group of adolescent rats received the same SSRI or vehicle

pretreatment and BDNF protein and monoamine content was

assessed in various brain regions 24 h later. We found
that 10 consecutive days of SSRI administration was

sufficient to cause changes in neuronal function.
Specifically, paroxetine treatment caused a significant
reduction in serotonin concentrations in both the

prefrontal cortex and hippocampus, while fluoxetine
reduced serotonin levels in the prefrontal cortex.

Paroxetine also caused a reduction in BDNF levels in
males, while fluoxetine increased BDNF levels in females.
Repeated treatment with these SSRIs caused only minor

changes in sucrose consumption and had no effect on

elevated plus maze behavior. These results suggest that
SSRIs can cause significant changes in neuronal mechanisms

associated with depression and suicidal-like behavior in
adolescents. Interestingly, these changes in neuronal
functioning did not translate into behavioral changes.
While not conclusive, these data suggest that chronic

treatment with the SSRI paroxetine may potentiate

depression by reducing serotonin levels and decreasing
BDNF levels.
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CHAPTER ONE
DEPRESSION IN ADOLESCENCE

Major depressive disorder (MDD) is a pervasive mental

disorder that affects both adult and pediatric
populations. This disorder is characterized by negative

mood accompanied by sleep or appetite disturbances,
delusions, irritability, anhedonia, impaired cognitive

functioning and feelings of worthlessness or excessive

guilt (Masi, Liboni, & Brovedani, 2010). There is also
considerable evidence that MDD is positively correlated

with comorbid psychopathology, substance abuse, and

attempted suicide (Kovacs, 1996; Kovacs, Goldston, &
Gastonis, 1993; Marttunen, Aro, Henriksson, & Lonnqvist,
1991; Rao, Weissman, Martin, & Hammond, 1993; Shaffer,

1988). This disorder is one of the most commonly diagnosed
mental health disorders in the United States, with

approximately one in every six individuals succumbing to
clinical depression during their lifetime (Kessler, Chiu,
Dernier, Merikangas, & Walters, 2005). MDD is also evident

in pediatric populations with a prevalence estimate of
2.5% (Birmaher et al., 1996). During adolescence the

prevalence of MDD ranges between 4% and 8% and,
astonishingly, the prevalence increases to 25% towards the
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end of the adolescent period (Kessler, Avenevoli, & Ries
Merikangas, 2001).

This high rate of MDD in adolescence is associated
with an increased risk of suicidal behavior. A national

survey on youth risk behaviors in high school students
reported that 8.5% of this population self-reported that
they had attempted suicide at some point in the past year.
Interestingly, the majority of these suicide attempts did
not use lethal methods (Grunbaum et al., 2004).

Furthermore, 16.9% of this national sample reported
seriously considering the act of suicide (Grunbaum et al.,

2004). This self-report rate of suicide attempts and
suicidal ideation is consistent with a 2006 report stating

that suicide was the third leading cause of death for
young people between the ages of 15 and 24 in the United

States (Keller et al., 2001).
Pharmacotherapeutic Treatment of Major Depressive
Disorder in Adolescent Populations
Due to the high rate of depression in pediatric

populations, the use of antidepressants is increasing. In
2002, 11 million antidepressant prescriptions were written

for adolescents and children within the United States

(Rigoni, 2004) . Unfortunately, clinical evidence for the
efficacy and safety of antidepressant medications is

2

limited in adolescent populations and the existing data is
often conflicting. Meta-analyses of antidepressant trials
have indicated that tricyclic (TCA) antidepressants do not
have a significant beneficial effect on depressive
symptoms in pediatric populations (Ambrosini, Bianchi,

Rabinovich, & Elia, 1993; Dujovne, Barnard, & Rapoff,
1995; Geller, Reising, Leonard, Riddle, & Walsh, 1999;
Michael & Crowley, 2002; Varley, 2003; Wittington,

Kendall, Fonagy, Cottrell, Cotgrove, & Boddington, 2004).
In contrast, published clinical trials have indicated that
serotonin reuptake inhibitors (SSRI) may be beneficial for
the treatment of MDD in juveniles, but other reports have

questioned the efficacy of these medications in pediatric

populations (Emslie et al., 2002; Emslie, Rush, Weinberg,
Gullion, Rintelmann, & Hughes, 1997; Keller et al., 2001;
Simeon, Dinicola, Ferguson, & Copping, 1990; TADS, 2004;

Wagner et al., 2003; Wagner, Robb, Findling, Jin,

Gutierrez, & Heydorn, 2004). For instance, clinical trials
have shown fluoxetine to be efficacious for children and
adolescents with major depression when compared to

placebo-treated groups (Emslie et al., 2004; Hetrick,
Merry, McKenzie, Sindahl, & Proctor, 2007) Paroxetine

treatment also significantly improves major depression in
adolescents (Emslie & Mayes, 2001; Keller et al., 2001).
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However, Emslie et al.

(2006) has also reported that

paroxetine-treated groups were not statistically different

from placebo-treated groups.

Serotonin Reuptake Inhibitors and the Risk
of Suicide in Pediatric Populations
Despite the evidence that SSRIs may be useful
therapeutics in the treatment of MDD for juveniles, there

are major concerns about their safety. Specifically, there

is evidence that SSRIs may increase the risk of suicide in
adolescents. In 2004, the FDA issued a "biack box" label

warning for all SSRI antidepressant medications used in
children and adolescents. The warning addresses the

potential increased risk of suicidal thought, tendencies,
and behaviors in juveniles during short-term SSRI

treatment for major depression. This warning also
concluded that minors should be stringently monitored (for
at least the first 4 weeks of treatment) for the emergence

of predispositional symptoms to suicide, which include

aggression, irritability, insomnia, and social withdrawal

(FDA, 2004). The decision of the FDA was based on the
results of a randomized controlled clinical trial, which
indicated that there was a pronounced increase in suicidal

behaviors and ideations in children not previously
characterized with suicidal tendencies. Specifically,
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suicidal behavior and ideations of children increased from
2% to 4% when treated with SSRIs (FDA, 2004; Hammad,

2004). The FDA later convened another meeting of its
scientific advisory committee and determined that the

black-box warning should be extended to late adolescence
and early adulthood as well (Laughren & Levin, 2006).
While the evidence that lead to this warning was

provocative, it did not suggest that an individual's

response to a particular antidepressant could be predicted
with any certainty. It is still very much in question
whether SSRI treatment increases the risk for suicide in

adolescents. Unfortunately, the controlled clinical trials

needed to adequately assess the increased risk of suicide
would require a large number of participants to show even
a small effect. It may not be plausible or ethical to

control for a majority of the factors that may
significantly impact the risk of suicide.
Thesis Statement

There are many variables that increase the risk of

suicide including genetic, social, psychological, and
biological factors, making the evaluation of the effect of
SSRIs on suicidal behavior difficult to assess in human
adolescents (Henry & Demotes-Mainard, 2006). Consequently,
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an animal model that is not confounded by comorbid

psychiatric disorders, biological or environmental

influences would enhance our understanding of the function
SSRIs in suicidal behavior during adolescence. Suicide is

a complex behavior, which is impossible to reproduce in a

single animal model. We can, however, duplicate aspects of
suicide by investigating the characteristics associated

with suicidal behavior, such as impulsivity, hopelessness,

aggression, and irritability (Malkesman et al., 2009). To
date, there has been very little research on the potential

mechanisms whereby SSRIs increase the risk of suicide
(Malkesman et al., 2009). Therefore, the purpose of this

investigation was to assess the effects of SSRI (e.g.,

fluoxetine and paroxetine) administration on risk-taking
and depressive behavior in adolescent rats. In addition,

neurochemical levels that are critically altered in human

suicide completers (e.g., serotonin and brain-derived

growth factor) were also measured after chronic SSRI
treatment.
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CHAPTER TWO

SEROTONERGIC, ADRENERGIC, AND HYPOTHALAMICPITUITARY -ADRENAL AXIS DEVELOPMENT IN RATS
When is Adolescence?

Adolescence is a developmental stage characterized by

greater levels of impulsivity, risk-taking,

novelty-seeking, with reductions in anxiety and decreased
stress reactivity compared to adults (Adriani, Seta,
Dessi-Fulgheri, Farabollini, & Laviola, 2003; Spear,

2000). It also marks the transition from childhood to

sexual maturity (Spear, 2000). The biological processes
involved in reaching adolescence appear to be very similar
across mammalian species including humans and rodents. The
time scale for this development varies across species,

because humans develop on a scale of months to years while

rats develop on a scale of days to weeks. Humans spend an
extended period of time in a prepubescent state and do not
reach puberty until 11 years on to 16 years of age. Rats
are born at a developmental stage which is roughly

equivalent to the third trimester of a human fetus, with
rats reaching sexual maturity (i.e., puberty) at
approximately five weeks (McCormick & Mathews, 2007) .

Although the age range for adolescence in rats is not

7

universally agreed upon (Spear, 2000), the period between

postnatal day (PD) 28 through 42 is a conservative range
based on physiological and behavioral development
(McCormick & Mathews, 2007; Spear, 2000) . Other

investigators suggest a broader range of adolescence that
can start as early as PD 20 in females and extend until

approximately PD 55 in males (Odell, 1990; Ojeda,
Urbanski, & Ahmed, 1986).

Adolescence is marked by biological and behavioral
changes which may have a pronounced impact on the efficacy
of antidepressants. Therefore, this chapter will be

dedicated to understanding the ontogeny of various systems
involved in antidepressant action. One general pattern

that emerges is that adrenergic systems develop much

slower than serotonergic systems.. This may explain why
antidepressants function in a different manner in immature

mammals when compared to adults (Murrin, Sanders, &

Byland, 2007) ;
Development of the Serotonergic System
Serotonin or 5-hydroxytryptamine (5-HT) is an

indolealkylamine synthesized within serotonergic neurons
and is found throughout the nervous system. The cell

bodies of serotonin neurons are mainly localized in the
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mid- and hind-brain (Tork, 1990) and innervate almost the
entire central nervous system (Rho & Storey, 2001). The
serotonergic system plays a role in modulating a wide
array of behavioral responses including aggression, mood,

appetite and arousal (Kaye, 2008; Miller & O'Callaghan,

2006; Siever, 2008; Young & Leyton, 2002). In particular,
it is thought that the rostral serotonergic projections
are involved in the pathology of various psychiatric

disorders (Jacobs & Azmitzia, 1992).
Considering the many roles of serotonin within the

CNS, it is not surprising that this neurotransmitter
system is one of the first to develop (Lauder, 1990;

Rajaofetra, Sandillon, Geffard, & Privat, 1989; Rho &

Storey, 2001). In neuroembryonic studies in rats, cells

containing serotonin-positive neurons are observed as
early as embryonic day 12, with serotonergic fibers
detected at embryonic day 14 (Murrin et al., 2007; Wallace

& Lauder, 1983). There is a rapid surge of neuronal and
dendritic serotonergic growth after birth, which lasts

until the end of the first postnatal week (Lidov &
Molliver, 1982; Loizou & Salt, 1970), with adult

serotonergic innervations patterns -established by the
third postnatal week (Dori, Dinopoulos, Blue, &
Parnavelas, 1996; Lidov & Molliver, 1982). In the raphe
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nucleus, synaptogensis of the serotonergic system is at

75% of adult levels by PD 15. The motor cortex continues

to mature with neuronal density increasing until around PD

35 (Dori et al., 1996). The neuronal density of serotonin
in the basal forebrain on the other hand, reaches adult

levels at around postnatal week two but declines during
the third week before increasing again (Dinopoulos, Dori,
& Parnavelas, 1997). Ultimately, serotonin levels are low

at birth and generally peak around PD 21 to 30 before

decline to adult levels (Loizou, 1972; Whitaker-Azmitia,
2005).

Serotonin binds to six pharmacologically different
G-coupled protein receptors, 5-141-1,-2,-4,-5,-6,-7/ and one

ligand-gated ion channel receptor, 5-HT3 (Murrin et al.,
2007). Several subtypes exist with each of the serotonin

receptor families. The density of serotonin receptors and
reuptake sites within the mammalian brain typically peak

prior to puberty (i.e., pre-adolescent period [PD 21-30]),
before decreasing to adult levels (Whitaker-Azmitia,
2005). For instance, serotonin receptor levels in the
striatum are at only 12% of adult levels at birth, but

rapidly increase to 150% by PD 21. The hippocampus and

cortex, on the other hand, increase to only 75% of adult
levels by PD 21 (Nelson, Herbet, Adrien, Bockaert, &
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Hamon, 1980) . By PD 15, 5-HTi receptor density in the-

brainstem is similar to adulthood (Whitaker-Azmitia,

Lauder, Shemmer, & Azmitia, 1987). In contrast, 5-HT2
receptors rapidly increase until PD 13 and then decline to

adult levels (Roth, Hamblin, & Ciaranello, 1991). In the
hippocampus, 5-HT5A and 5-HT7 receptors fluctuated during
the' pre-weanling period before stabilizing in adulthood
(Garcia-Alcocer, Segura, Garcia, Martinez-Torres, &

Miledi, 2006).
Development of the Adrenergic System

Norepinephrine is a member of the catecholamine

family and functions as both a neurotransmitter and a
hormone. Norepinephrine is synthesized from dopamine by
the enzyme dopamine p-hydroxylase. In the peripheral

nervous system, norepinephrine is produced by the adrenal
medulla and is released into the circulatory system. In
the central nervous system, noradrenergic neurons are

localized in the locus coeruleus and lateral tegmental
field (Rho & Storey, 2001). These neurons project to a
wide array of brain regions, with the highest
concentration of fibers extending to the hypothalamus (Rho

& Storey, 2001). Adrenergic neurons from the locus

coeruleus and lateral tegmental field also innervate the
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spinal cord and cerebellum through a dorsal fiber bundle

and nearly all of the norepinephrine is release into the
cortex, limbic system, and thalamus originates from these

regions.
Noradrenergic neurons begin to differentiate between
embryonic day 10 to 13 in rats (Lauder & Bloom, 1974).

From this point on, the adrenergic system follows a linear
pattern of development within the central nervous system,

proliferating 100- to 1000-fold by adulthood (Coyle,
1977) . By PD 15, synaptogensis of norephinephrine neurons
in the locus coeruleus is only at about half of adult

levels (Lauder & Bloom, 1974). Noradrenergic projections
and cell bodies appear during gestation but further

maturation of cortical projections and synaptic formations

continue to proliferate primarily during the first 3 weeks
of age (Loizou, 1972). Generally, noradrenergic levels

continue until around PD 30 to PD 40 when they reach adult
concentrations. However, in the cerebellum and brainstem

norepinephrine reaches maturation up to a week earlier
than the rest of the system (Konkol, Bendeich & Breese,

1978) .
Norephinephrine binds to three pharmacologically and
molecularly different G-coupled protein receptors, oti, 0C2f
and [3, each with three subtypes, oeiA, ot iB, ot XD, ot2A, a2B,
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a2Cf and

fi2f £3 (Rho & Storey, 2001) . The «i receptors

rapidly proliferate until PD 20, when the level of this
adrenergic receptor decrease until reached adult levels.

This overshoot correction may take weeks to occur. Beta

receptors in the cerebral cortex develop very similarly,
surpassing adult levels by the third postnatal week, and

then slowly decline over the next few months (Murrin et

al., 2007).

In conclusion, the serotonergic system reaches
maturity at a much younger age, than the adrenergic

system, an effect evident across mammalian species (Murrin
et al., 2007). For example, the development of 5-HT
innervation is completed during the pre-adolescent period

in rats, which is two weeks earlier than the noradrenergic
system. At birth, the uptake transporters for serotonin
are fully developed, unlike NE which reaches adult levels

21 days later. The different maturation rates of
norepinephrine and serotonin neurotransmitter systems

suggest the possibility that psychoactive drugs may induce

unique effects depending on age (Murrin et al., 2007).
Consistent with this idea, clinical trials have repeatedly

shown that TCA antidepressants are ineffective on children
with major depressive disorder (Geller et al., 1999;
Michael & Crowley, 2002; Varley, 2003; Wittington et al.,
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2004). The underdeveloped noradrenergic system could

definitely play a role in this finding (Murrin et al.,
2007).

The Development of the HypothalamicPituitary-Adrenal Axis
Adolescence is a period of maturation that prepares

an animal for the transition into adulthood, a phase
defined by the ability to sexually reproduce and survive

independently (McCormick & Mathews, 2007). The HPA axis is

important due to its involvement in the physiological
reactions to environmental and psychological stressors.
This system provides the ability to cope during aversive

or threatening situations. Resent evidence has

demonstrated a sensitivity period during adolescence where
the HPA axis can influence neurological programming, such

as increasing neuronal plasticity. This development period
has only been shown previously in prenatal development

(Grant, Compas, Stuhmacher, Thurm, McMahon, & Halpert,

2003; McCormick & Mathews, 2007; Spear, 2000) .
The HPA axis modulates neuroendocrine system

functioning through the actions of glucocorticoid
hormones. Under the control of the hypothalamus, hormones

are secreted from the paraventricular nucleus, including

most notably arginine vasopressin (AVP) and corticotropin
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releasing hormone (CRH)

(Antoni, 1986). These hormones, in

turn, control the release of adrenocorticotropin hormone

(ACTH) from the anterior pituitary, which then stimulates
the secretion of glucocorticoids from the adrenal cortex

(Keller-Wood & Dallman, 1984). Glucocorticoids play an

important role in neuronal development and plasticity and
can influence neurogenesis, synaptogenesis, neuronal

excitability, and atrophy (McEwen, 2000). Glucocorticoids
are also important in protein synthesis and metabolism of

neurotransmitters (Keller-Wood & Dallman, 1984).
The purpose of the HPA axis is to regulate

homeostatic mechanisms that after altered by
stress-inducing events, thus preventing a potential
overreaction to stressors which may have a deleterious
impact on the organism. The HPA axis can be activated by a
continuum of psychological and physiological stressors,

both innate and learned (McCormick & Mathews, 2007).
Glucocorticoids can facilitate attention, memory

formation, activate energy stores, and improve
cardiovascular tone to enhance an organism's ability to

cope with a particular stressor. Conversely, prolonged

release of these glucorticoids can cause robust effects on
the peripheral and central nervous systems or an organism

(McEwen, 2000). The HPA axis also has the ability to
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self-regulate to protect against the harmful effects of

prolonged exposure to glucorticoids. Glucocorticoids can

inhibit the release of ACTH which in turn suppresses the
release of more glucocorticoids and in the way, diminishes
the physiological responses to a stress-inducing stimulus

(Dallman, Akana, Jacobson, Levin, Cascio, & Shinsako,
1987; Keller-Wood & Dallman, 1984).

Components of the HPA axis reach adult levels at
various points in development. Glucocorticoid receptors

reaches maturity at around PD 14, much sooner than ACTH
concentrations (Walker, Sapolsky, Meaney, Vale, & Rivier,

1986) and CRH-responsive cells (Senovilla, Garcia-Sancho,
& Villalobos, 2005), which reach adult levels at about 60
days of age. Corticosterone levels reach adulthood at four
weeks of age (McCormick & Mathews, 2007; Sapolsky &

Meaney, 1986; Schoenfeld, Leathen, & Rabii, 1980).

Consequently, the negative feedback system has not fully

developed by preadolescence. The implication of this
maturational lag is that stressful events will cause a
delayed onset and prolonged release of corticosterone
(Goldman, Winget, Hollingshead, & Levine, 1973).

Investigators have also attributed a prolonged release of
glucocorticoids to the undeveloped parvocelluar PVN (Viau,

Bingham, Davis, Lee, & Wong, 2005). By two months of age,
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ACTH- (Walker et al., 1986) and CRH-responsive cells
(Senovilla et al., 2005) within the pituitary reach

maturity.
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CHAPTER THREE
NEUROBIOLOGY OF SUICIDAL BEHAVIOR

Several lines of evidence suggest that depression and
suicide may be mediated by common mechanisms. For example,

psychological autopsies in suicide completers have
identified MDD as a major contributor to suicidal behavior

(Van Heeringen & Marusic, 2003). In addition, the rate of

suicide attempts is increased in people diagnosed with MDD
when compared to the general population (Marttunen et al.,
1991; Rao et al., 1993; Shaffer, 1988). However, other

evidence suggests that suicide is a unique psychopathology
and not simply a symptom of depression. In particular, the

majority of people diagnosed with MDD will not attempt
suicide, and some individuals who commit suicide do not
suffer from MDD. Thus, it is clear that depression alone
is not sufficient to explain suicidal behavior. Recently,
other risk factors for suicidal behavior, such as

impulsivity and aggression, have been identified. It is
now clear that the neurobiological mechanisms of suicidal

behavior probably involve a number of different distinct
brain circuits.
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Neurobiology of Depression
Brain Regions
Several brain regions and neuronal circuits that

regulate emotion, reward, and executive functioning have
been implicated in depression (Berton & Nestler, 2006).
Brain regions such as the hippocampus and neocortex are

believed to .mediate the cognitive aspects of depression,
which includes feelings of worthlessness, hopelessness,
guilt, and suicidal tendencies (Nestler, Barrot, DiLeone,
Eisch, Gold, & Monteggia, 2002). The nucleus accumbens,
also called the ventral striatum, and the amygdala, are

thought to be important for emotional memory (Nestler et
al., 2002). FMRI studies on depressed patients have
demonstrated abnormalities in the frontal cortex,

cingulate cortex, hippocampus, amygdala, and striatum
(Liotti & Mayberg, 2001; Manji, Drevets, & Charney, 2001;
Zhu et al., 1999). Multiple meta-analyses have indicated
that patients with recurrent depression have smaller

hippocampal volumes (Campbell & MacQueen, 2006; Campbell,
Marriott, Nahmias, & MacQueen, 2004; Videbech & Ravnkilde,

2004). This reduction is usually associated with memory

deficits which are common among patients with mood

disorders. Studies on amygdala volume provide inconsistent
results; however, enlarged amygdala volume has been
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reported much less frequently in patients with MDD

(Bremner, Narayan, Anderson, Staib, Miller, & Charney,
2000; Frodl et al., 2002; MacMillan et al., 2003), than
patients with smaller amygdala volume (Caetano et al.,

2004; Hastings, Parsey, Oquendo, Arango, & Mann, 2004;

Rosso, Cintron, Steingard, Renshaw, Young & Yurgelun-Todd,
2005; Sheline, Gado, & Price, 1998; Siegle, Konecky,

Thase, & Carter, 2003). There is evidence that the
striatum is smaller in some depressed adults (Greenwald et

al., 1997; Husain et al., 1991; Krishnan et al., 1992).

Monoamine Hypothesis
Over 50 years ago, antidepressants revolutionize the

clinical research field by indicating that depression is a
disorder that could be treated by increasing synaptic

neurotransmitter levels by inhibiting reuptake or
preventing the degradation of released monoamines (Nestler
et al., 2002). This finding plus studies showing that
resperine, a drug that depletes monoamine stores, can
induce depressive symptoms lead to the monoamine

hypothesis. This hypothesis simply states that depression
is caused by decreased monoamine activity.
Neurotrophic Hypothesis
While abnormalities in monoamine functioning are

still considered to be important for depression, a growing
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amount of research suggests that monoamine dysfunction
cannot be the sole cause of depressive symptoms (Nestler

et al., 2002). Evidence in support of this view include
studies showing that:

(1) monoamine depletion does not

cause depression in most people (Ruhe, Mason, & Schene,
2007),

(2) psychostimulants, like amphetamine and cocaine,

increase levels of monoamines but do not alleviate
«
symptoms of depression (Paul, 2001), and (3) acute

administration of antidepressants, which induce an
immediate increase in synaptic monoamine levels do not
alleviate depressive symptoms (Berton & Nestler, 2006). An
alternative to the monoamine hypothesis theory has

recently been proposed that focuses on the dysfunctions in
the neurotrophic factor, brain derived neurotrophic factor

(BDNF). Neurotrophic factors are important for the
development and maintenance of neurons and synaptic

connections (Shirayama, Chen, Nakagawa, Russell, & Duman,
2002) . The neurotrophic hypothesis of depression states

that a deficiency in BDNF in specific brain regions, such

as the hippocampus, results in depressive symptoms. This
hypothesis is supported by animal research demonstrating
that virtually all antidepressants up-regulate the

expression of BDNF in the dentate gyrus and hippocampus

(Nibuya, Morinobu, & Duman, 1995). This up-regulation of
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BDNF has also been demonstrated in the hippocampus of
humans (Chen, Dowlatshahi, MacQueen, Wang, & Young, 2001).

In addition, animal research has demonstrated that

infusions of BDNF into the midbrain, dorsal raphe nucleus,
dentate gyrus, or hippocampus causes antidepressant-like

responses in the forced swim test and learned helplessness
model (Shirayama et al., 2002; Siuciak, Lewis, Wiegand, &

Lindsay, 1997). Interestingly, the antidepressant effects
of BDNF infusion actually persist longer than classical
antidepressants

(Shirayama et al., 2002) .

Hyperactivity of the Hypothalamic-PituitaryAdrenal Axis

Hyperactivity of the HPA axis is another alternative
theory to the original monoamine hypothesis. The HPA axis

is the primary system for reacting to acute and chronic
stress. The HPA axis theory postulates that increased

release of cortisol (also called hypercortisolism)
produced by chronic stress leads to depressive symptoms.
Under stress/ cortisol and other glucocorticoids cause the

hippocampus and paraventricular nucleus to exert a

powerful inhibition feedback on the HPA axis to regulate
and promote healthy cognition (Nestler et al., 2002).

However, prolonged cortisol release can damage hippocampal
neurons resulting in reduction in dendritic arborization

22

(Nestler et al., 2002). Moreover, some studies have shown
that depressed patients have reduced hippocampal volumes

compared to non-depressed controls (Bremner et al., 2000;
I

Sheline, Sanghavi, Mintun, & Gado, 1999). Hyperactivity of
the HPA axis in depression is supported by evidence that a

large majority of individuals exhibit aberrant, over

activation of the HPA axis, which can be reduced through
antidepressant administration (Arborelius, Owens, Plotsky,

& Nemeroff, 1999; De Kloet, De Kock, Schild, & Veldhuis,
1988; Holsboer, 2001; Sachar & Baron, 1979).

Adolescent Depression
Adolescent depression is associated with a
constellation of endocrine, physiological, chemical and

morphometric neurological abnormalities.(Davidson et al.,
2002) . The symptoms of major depression are expressed

differently depending on maturational stage but, in
general, poor social, cognitive, and interpersonal skills,

as well as a significant risk for self-harm, are
characteristics common among all ages (Reed, Happe, Petty,

& Byland, 2008). Adolescent FMRI studies have revealed
that males with MDD have a smaller volume and reduced
white matter in the left anterior cingulate cortex

compared to control (Hastings et al., 2004). Post-mortem

studies also indicate that the anterior cingulate cortex
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of depressed adolescents is reduced in size (Campbell &
MacQueen, 2006). Adolescents with depression have smaller
bilateral hippocampal volumes when compared to healthy

controls (Hickie et al., 2005).
Neurobiology of Impulsivity and Risk-Taking

Kochansky (1973) demonstrated that after presenting a
depressive mood-stimulating film, suicide attempters
exhibited a greater preference for risk-taking compared to

suicide threateners, non-suicidal psychiatric patients or
healthy controls. Clinical investigations have revealed

several brain regions involved in risk-taking decision

processes. Lesions of the prefrontal cortex and
orbitofrontal cortex both lead to impaired decision making

abilities on a risk-taking task (Bechara, Damasio, Tranel,
& Damasio, 1997; Rogers et al., 1999). FMRI studies on
healthy adults during a risk-taking task have shown
activation in the orbitofrontal cortex, inferior
prefrontal cortex, ventrolateral and ventromedial

cortecies, insula, and parietal regions (Critchley,
Mathias, & Dolan, 2001; Elliott, Dolan, & Frith, 2000;
Elliott, Rees & Dolan, 1999; Liu, Powell, Wang, Gold,

Corbly & Joseph, 2007; Paulus, Rogalsky, Summons,

Feinstein, & Stein, 2003). Activation of the anterior
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cingulate cortex and lateral prefrontal cortex have been

implicated in the regulation of inhibitory control (i.e.

impulse control) when making a risk-taking decision (Lee,
Chan, Han, Leung, Fox, & Gao, 2008).
Adolescent Risk-Taking Behavior

During adolescence, dramatic neurobiological changes
occur to brain regions associated with risk-taking. These

changes begin with a massive growth of synaptic and axonal
fiber densities in the amygdala and prefrontal cortex
(Cunningham, Bhattacharyya, & Benes, 2002) . These fibers

continue to grow and expand until the late-adolescent
period (Cunningham et al., 2002). During this
late-adolescent period, dendritic pruning rapidly

increases in the amygdala, nucleus accumbens, and

prefrontal cortex (Andersen, Thompson, Rutstein,
Hostetter, & Teicher, 2000; Teicher, Andersen, &
Hostetter, 1995; Zehr, Todd, Schulz, McCarthy, & Sisk,

2006). This rapid synaptic pruning during late-adolescence

is believed to occur in response to the overproduction
that took place during the start of adolescence.
Furthermore, there is a time-dependent difference between
the development of the limbic sub-cortical and frontal

cortical regions. In particular, the prefrontal cortex is
the last region to undergo active myelination (Andersen et
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al., 2000; Giedd, 2004; Teicher et al., 1995). Overall,

regions specific to emotion and executive functioning are
still developing throughout the adolescent period.
Furthermore, the late development of these important

regions may underlie the heightened emotional reactivity
and sensitivity due to the without the ability to override

inappropriate thoughts and behaviors mimicking the under

developed sub-cortical (Casey, Jones, & Hare, 2008).
Central Nervous System Abnormalities
Associated with Suicidal Behavior
Hypofunctionality of the serotonergic system is a

common finding in suicide completers (Mann, 2003). For
example, postmortem studies have found lower levels of

both serotonin and 5HIAA (the main metabolite for

serotonin) in brain stem tissues, along with lower level

of 5HIAA in the cerebrospinal fluid (Mann et al., 1996).
Investigators have also found abnormalities in the
serotonergic system with decreased presynaptic serotonin
transporter sites in the occipital cortex, hypothalamus,
brainstem, and prefrontal cortex (Mann, Arango, Marzuk,
Theccanat, & Reis, 1989; Mann, Henteleff, Lagattuta,

Perper, Li, & Arango 1996) . The ventral-medial prefrontal

cortex, an area related to impulsivity and aggression, has
also been shown to have less serotonergic transporter
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binding, in all cortical layers (Arango, Underwood, Gubbi,

& Mann, 1995; Mann, 2003).
Evidence of noradrenergic system impairment in

suicide completers has also been reported. Specifically,
the number of noradrenergic neurons are reduced in the

locus coeruleus'and lower brainstem of suicide completers

(Arango, Underwood, & Mann, 1996; Ordway, Widdowson,
Smith, & Halaris, 1994). Moreover, compensatory increases
in prefrontal ot2r and p-adrenergic receptors, and tyrosine

hydroxylase activity have been reported (Mann, 2003). This
overactivity of the noradrenergic system and HPA axis is
associated with severe anxiety and agitation (Fawcett,

Busch, Jacobs, Kravitz, & Fogg, 1997).
Postmortem studies have shown that levels of BDNF may

be region specific with significant reductions in the

prefrontal cortex and hippocampus of suicide completers
(Karege, Vaudan, Schwald, Perroud, & La Harpe, 2005). In

addition, the BDNF receptor, TrkB, is also significantly
reduced in the prefrontal cortex and hippocampus of

suicide completers compared to normal controls (Karege et

al., 2005).
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CHAPTER FOUR
SEROTONIN REUPTAKE INHIBITORS AND ADOLESCENCE
The rate of SSRIs prescribed for adolescents has
risen over the last decade, despite the risk of suicidal

ideation and hostility induced by the administration of

these drugs (Clavenna, Bonati, Rossi, De Rosa, 2004; FDA,

2004; Murray, de Vries, Wong, 2004; Schirm, Tobi, Zito, &

de Jong-van den Berg, 2001). This increase in SSRI

prescriptions is thought to be due in part to the poor
efficacy and side effects of alternative treatments, such

as tricyclic antidepressants (Hazell, O'Connell,
Heathcote, & Henry, 2002). A recent meta-analysis of

published and unpublished double-blind clinical trials,

revealed an increased risk of suicidal thoughts, behaviors

and adverse effects for children and adolescents
prescribed SSRI medications compared to those who received
placebos (Hetrick et al., 2007). Fluoxetine, however, is
the only SSRI that was consistently effective in

attenuating depression symptoms (Hetrick et al., 2007).

Thus, fluoxetine is the only medication to have an
acceptable risk-benefit ratio when compared to all other

SSRIs (Cheung, Emslie, & Mayes, 2005). Interestingly,

another widely used medication in the pediatric
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population, paroxetine, has demonstrated no clinical
efficacy in treating depression (Cheung et al., 2005).

Hence, this chapter discusses the neurochemical and

behavioral effects of fluoxetine and paroxetine within the
adolescent population.

SSRIs are classified by their ability to selectively

increase extracellular levels of serotonin by inhibiting
presynaptic reuptake and are at least 10-fold more

selective for serotonin than for norepinephrine reuptake

(Feighner & Boyer, 1996). Fluoxetine was the first SSRI
medication to be approved by the FDA for ‘the treatment of
depression and the first to be found efficacious for the

treatment of maj or depression in children and adolescents
(Emslie et al., 1997; 2004). The major side effects

associated with tricyclic antidepressants, such as
drowsiness, ataxia and memory loss are not exhibited by

fluoxetine, because it has very weak binding affinity to
histaminergic and cholinergic receptor sites (Hyttel &

Larsen, 1985) .

Paroxetine (trade names, Paxil and Seroxat) was the
third SSRI to be approved by the FDA for the treatment of
depression in adults and is one of the most widely

prescribed antidepressant medications in the United
States. A phenylpiperidine derivative, paroxetine is
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chemically unrelated to any other antidepressants
currently in use (Bourin, Chue, & Guillon, 2001).

Paroxetine is one of the most specific and potent SSRIs

with the highest affinity for serotonin transporters
(Mellerup & Plenge, 1986; Owens, Morgan, Plott, &
Nemeroff, 1997). By comparison, fluoxetine has only a
tenth of the affinity that paroxetine possesses for

serotonin transporters (Owens et al., 1997). Paroxetine

also has a moderate affinity for norepinephrine
transporters (Nemeroff & Owens, 2003). Like fluoxetine,

paroxetine is considered a relatively "clean" drug in
comparison to older tricyclic compounds and monoamine
oxidase inhibitors because it has very little to no

binding affinity in rats to the adrenergic (oti, a2) r
dopamine (Di, D2) , serotonergic (5-HTiA, 5-HT2A) , histamine

(Hi) receptors and a weak affinity to the noradrenaline
and muscarinic acethylcholine receptors (Hyttel, 1994;

Owens et al., 1997).
Effects of Repeated Serotonin Reuptake Inhibitors
Administration in Adolescents Rats
Although it is believed that fluoxetine is overall

effective in adolescent psychiatry, there are reports of

adverse drug effects such as suicidality, agitation,

worsening of depression and anxiety within this population
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(March et al,, 2004). Furthermore, there is a deficit in

research looking at not only the effect of fluoxetine on

behavioral and neurochemical alterations, but the effect
that other widely used SSRIs, such as paroxetine, may

have. This section will highlight the effects of

fluoxetine and paroxetine in various areas of research.

Neurochemical Alterations

Rats administered fluoxetine (5 mg/kg, oral) for two
weeks beginning on PD 25, but not PD 50, had an increase

in serotonergic transporter densities in the frontal

cortex when compared to rats treated with vehicle
(Wegerer, Moll, Bagli, Rothenberger, Ruther, & Huether,

1999). The absence of an effect in rats administered the

same dose during the end of the adolescent period (PD 50)
indicates that fluoxetine treatment has a unique effect

when given prior to late-adolescence. The density of

noradrenergic transporters in the frontal cortex remained
unchanged for both groups (Wegerer et al., 1999).
The "high-anxiety/stress" mouse strain, BALB/cJ,
exhibited lower levels of serotonin and 5HIAA after a two

week administration of fluoxetine during adolescence,
relative to the "low-anxiety/stress" C57BL/6J mouse strain
(Anisman, Haylay, Kelly, Borowski, & Merali, 2001;
Norcross et al., 2008). There were also lower hippocampal
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volumes in the BALB/cJ strain compared to C57BL/6J strain
but no significant difference in frontal cortex size
(Norcross et al., 2008).

Alterations in the neurogenesis of hippocampal

neurons have been implicated in both the pathology and
treatment of depression (Jacobs, Praag, & Gage, 2000).
Norrholm and Ouimet (2000) found that three weeks of

chronic fluoxetine during adolescence (PD 21-45) arrested

age-associated dendritic spine development in the CAI
hippocampus. In contrast, acute treatment with fluoxetine
increased dendritic length and spine density (Norrholm &
Ouimet, 2000). These results were surprising because

chronic fluoxetine treatment in adults has been shown to
increase cell proliferation in the hippocampus (Huang &
Herbert, 2006; Malberg, Eisch, Nestler, & Duman, 2000;
Marcussen, Flagstad, Kristjansen, Johansen, & Englund,

2008) .
In contrast to fluoxetine, there have been no chronic
paroxetine studies in adolescent rodents that assess

neurochemical changes. Thus, it is unclear at this point,
if paroxetine alters markers of suicide or depression.

Behavioral Alterations
Very few behavioral changes have been found after

adolescent exposure to chronic fluoxetine in rodents. No
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significant differences were found in the duration spent
on open arms using an elevated plus maze after fluoxetine

treatment during postnatal week three through seven

(LaRoche & Morgan, 2007). In addition, Norcross and

colleagues (2008) found that administering clinically

relevant doses of fluoxetine to adolescent mice (3-7
weeks) did not cause any significant changes on assays for

fear-, anxiety- and stress-like behaviors when tested in
adulthood under drug-free conditions. Furthermore,

adolescent administration of fluoxetine did not produce
any alterations in anxiety-related behaviors in adulthood,

such as on the elevated plus-maze or forced swim task.

Despite two early accounts that fluoxetine treatment
reduced conditioned fear after adolescent treatment
(Burghardt, Sullivan, McEwen, Gorman, & LeDoux, 2004),

some researchers have dismissed these accounts as not

being consistent with the general trend (Norcross et al.,
2008) .

Thirty-day chronic administration of paroxetine
beginning on PD 33 caused a reduction in body weight that

is hypothesized to be the result of reduced food
consumption (de Jong, Pattij, Veening, Waldinger, Cools, &

Olivier, 2005). This reduced consumption was believed to
be caused by the activation of 5-HTiB/2c receptors
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(Simansky, 1996). The same chronic paroxetine regimen also

caused anxiety-like performance on the elevated plus maze
when tested in adulthood.

Pharmacokinetics of Serotonin Reuptake
Inhibitors in Adolescence
Fluoxetine is currently the only SSRI with an active

metabolite, norfluoxetine, which exhibits clinical
relevance. Norfluoxetine is not only a potent

antidepressant; it also inhibits cytochrome P450 isoenzyme

(Fuller, Snoddy, Krushinski, & Robertson, 1992). In
humans, fluoxetine has a half-life of six days, with a 14
to 21 day half-life for its active metabolite (Newhouse,

Ko, & Richter, 1996). Paroxetine has a significantly

shorter half-life of 10 to 33 hours (Goodnick & Goldstein,
1998). Fluoxetine also exhibits a slower onset of
therapeutic efficacy compared to paroxetine (De Wilder,
Spiers, Mertens, Bartholome, Schotte & Leyman, 1993).

The

extended half-life of fluoxetine appears to be

advantageous in protecting against sporadic noncompliance,

a missed dose or the occurrence of withdrawal phenomena

(Stokes & Holtz, 1997). Furthermore, Weiss and Gorman
(2005) found trends across pharmacokinetics of different

antidepressants. The results of their work demonstrated
that those medications with shorter half-lives generally
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having an increased risk of suicidal ideations and
behaviors.

It is important to consider the clinical relevance of
an antidepressant administered to rodents. To cause a

significant level of serotonin transporter inhibition

within the CNS, the minimum therapeutic dose of fluoxetine
for humans is 1 mg/kg (Wegerer et al., 199.9; Wong,

Bymaster, Reid, & Threlkeld, 1983). Because rats

metabolize fluoxetine roughly ten times faster than

humans; the clinically equivalent dose for rat should
range around 5 to 15 mg/kg (LaRoche & Morgan, 2007).

Fluoxetine has been administered to rodents orally
(Santarelli et al., 2003), by intraperitoneal injection

(Kodama, Fujioka, & Duman, 2004; Malberg et al., 2000;

Marcussen et al., 2008), and by osmotic pumps (Huang,
Bannerman, & Flint, 2008; Huang & Herbert, 2006). Most

commonly, fluoxetine has been administered

intraperitoneally at 5 mg/kg (Cowen, Takase, Fornal, &
Jacobs, 2008; Norrholm & Ouimet, 2000) and 10 mg/kg (Mason

et al., 2009; Reed et al., 2008). Enhancement of
hippocampal neurogenesis or proliferating cell survival
was not altered by prolonged administration of fluoxetine

(5 mg/kg)

(Cowen et al., 2008). However, acute treatment

of fluoxetine (5 mg/kg) did increased dendritic length and
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spine density (Norrholm & Ouimet, 2000). Rats treated with

fluoxetine (10 mg/kg) had a significant decrease in
depressive-like behaviors using the forced swim task (Reed

et al., 2008) .
Paroxetine on the other hand, has been used in a

range of different dosages, from 0.1 mg/kg up to 12 mg/kg
in rodents (Casarotto & Andreatini, 2007; De Vry, Maurel,
Schreiber, de Beun, & Jentzsch, 1999; Draiper et al.,

2007; Gervasoni et al., 2002; Konkle, Sreter, Baker &
Bielajew, 2003). However, there is very little research
done in the adolescent rodents, therefore the range doses

provided include adult studies as well.
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CHAPTER FIVE

THESIS PROPOSAL AND HYPOTHESIS
Major depression is not an uncommon problem in human

adolescents and those adolescents who
suffer from clinical
/

depression are at a much greater risk of committing

suicide (Shaffer et al., 1996). Unfortunately, many of the
medications that are effective in adults in relieving the
symptoms of depression are ineffective in adolescent
populations. The most popular class of antidepressants,
the SSRIs, can induce suicidal thought in adolescents. The

mechanism for this paradoxical increase in suicidal
ideation and behavior is unknown and limited research has

been conducted on this topic. Thus,-the goal of the
present investigation was to assess the chronic effects of

SSRI treatment in adolescent rats on behavioral and

neurochemical measures associated with depression and
suicidal behavior in humans. Paroxetine and fluoxetine

were the SSRIs investigated. Paroxetine was chosen because

it is highly prone to increase suicidal behavior in humans

(Tiihonen, Lonnqvist, Wahlbeck, Klaukka, Tanskanen, &
Haukka, 2006). Moreover, paroxetine has shown very little

clinical efficacy in reducing the symptoms of depression
in adolescents (Emslie et al., 2006; Tiihonen et al.,
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2006). Fluoxetine was chosen as a comparator, because it
has a much lower risk value for inducing suicidal behavior
and is an effective treatment for depression in human

adolescents. Rats were treated with paroxetine (2.5 or 10

mg/kg), fluoxetine (10 mg/kg) or vehicle for ten
consecutive days starting on PD 35. This injection period
was chosen because it is analogous to middle adolescent

period in humans (Spear, 2000). Separate groups of rats
were used for the behavioral and neurochemical assays and
testing began 24 hours after the last drug administration.

Behavioral measures were assessed on a sucrose
preference task and an elevated plus maze tasks. The
sucrose preference task, which measures reward sensitivity
or anhedonia, is a choice procedure where rodents are

given an opportunity to drink from a bottle containing
water sweetened with sucrose or a bottle of tap water.

This measure was chosen because it is sensitive to

procedures that induce depressive symptoms in rats (i.e.,
unpredictable shock and neonatal isolation) and to
antidepressant treatment (Katz, 1982). In addition, the

sucrose preference task does not involve aversive stimuli,
is easily measured, and can be tested repeatedly. The
second measure was the elevated plus maze task. The
elevated plus maze procedure is the most common method for
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measuring anxiety in rodents and is also used as a measure

of impulsivity (Dawson & Tricklebank, 1995; Handley &

McBlane, 1993; Meyer, Piper, Vancollie, 2006; Rodgers &
Cole, 1994). The elevated plus maze procedure involves

placing rats on an elevated apparatus shaped like a plus,

with two enclosed arms and two open arms. The amount of
time spent in the open and closed arms is measured. The

more time spent in the open arms indicates lower levels of
anxiety and greater levels of impulsivity. The measure was

chosen 'because it is a well-validated measure and can be
completed in a short period of time. We hypothesized that

repeated treatment with paroxetine would decrease sucrose
preference and increase the amount of time, spent in the

open arm of the elevated plus maze when compared to

vehicle- and fluoxetine-treated rats. We also hypothesized

that repeated fluoxetine treatment would not alter either
behavioral measure.
The neurochemical measures included monoamine content
and BDNF levels within the prefrontal cortex and

hippocampus. Monoamine levels were measured by high
performance liquid chromatography with

electroelectrochemical detection (HPLC-EC). BDNF levels
were measured by enzyme-linked immunosorbent assays
(ELISA). We expected that chronic paroxetine treatment
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would decrease serotonin and BDNF levels when compared to
vehicle- and fluoxetine-treated rats. We expected that

chronic fluoxetine would not alter any of our
neurochemical measures when compared to vehicle-treated

rats.
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CHAPTER SIX
METHODS
Animals

A total of 130 male and female rats (n = 5-9 per

group) of Sprague-Dawley descent (Charles River
Laboratories, Wilmington, MA), born and raised at

California State University, San Bernardino, were used.
Litters were culled to 10 pups on PD 3 and housed with the
dam until PD 25. After weaning, rats were housed (4-6 rats
per cage) with same-sex littermates. Rats in the

behavioral experiment were single housed for the duration

of the sucrose preference test. The colony room was

maintained at 22-24° C and kept under a 12-hr light/dark
cycle. All animals were treated according to the "Guide
for the Care and Use of Mammals in Neuroscience and

Behavioral Research" (National Research Council, 2003)
under a research protocol approved by the Institutional

Animal Care and Use Committee of CSUSB.
Apparatus
The elevated plus maze was made of black plastic and

consists of two perpendicular, intersecting runways

(110.5 x 10.2 cm) located 70 cm above the floor (San Diego
Instruments, CA). One of the runways contains two "closed
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arms" with 30.5 cm high walls enclosing the planks and the
other runways have no walls or "open arms". The plus maze

was placed in the center of a quiet dimly lit room

(30 watt bulb) that was equipped with a video camera
positioned above the maze.
Drugs

Fluoxetine hydrochloride and paroxetine hydrochloride
were obtained from Sigma-Aldrich (St. Louis, MO). Both

fluoxetine and paroxetine were dissolved in dimethyl

sulfoxide (DMSO) and injected intraperitoneally (IP) at a

volume of 1 ml/kg.
In Vivo Drug

Rats received paroxetine (2.5 or 10 mg/kg),
fluoxetine (10 mg/kg) or vehicle once daily from PD 35 to

PD 44.
Experiment 1: Sucrose Preference
and Elevated Plus Maze

Sucrose Preference Procedure

Four days before beginning drug injections rats were
trained on the sucrose preference task using a two bottle

choice test. On the first day, rats were singly housed and

habituated to drinking from two bottles both containing
water for one day. On the next three days, one of the
water bottles was replaced with a bottle containing a 2%
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sucrose solution. The bottles were weighed and refilled
each day at the same time in the morning. The position of
the bottles was switched each day to avoid position
preferences. Following the initial sucrose procedure, rats

were returned to group housing. After the last drug
injection, rats were returned to individual housing and a
final sucrose test given. Sucrose preference was defined

using the following formula:

[volume of sucrose ingested/

(the volume of water ingested + volume sucrose
ingested)

x 100]

(Rygula, Abumaria, Flugge, Fuchs, Ruther,

& Havemann-Reinecke, 2005; Strekalova, Spanagel, Bartsch,
Henn, & Gass, 2004).
Elevated Plus Maze Procedure

Immediately following the sucrose test, rats were
individually brought into the test room and placed in the

center of the maze facing the open arm. Testing lasted 5
min. Time(s) in the open and closed arms, as well as
entries, was scored from the videotapes. A similar
elevated plus maze procedure has been described previously
(Bolanos, Barrot, Berton, Wallace-Black, & Nestler, 2003;

Frussa-Filho, Barbosa-Junior, Silva, Da Cunha, & Mello,

1999; Patisaul & Bateman, 2008). All four paws crossing
the threshold defined entire into open or closed arms and
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entire into the center of the maze was defined by only two

paws crossing.

Experiment 2: Serotonin Content and Brain
Derived Neurotrophic Factor Assays
Twenty-four hours after the last drug injection, rats
were rapidly decapitated and their prefrontal cortex,
hippocampus, and amygdala removed. The tissue sections for
each animal were divided into two sections and frozen at
-80 °C until time of assay. Trunk blood samples were also

collected for plasma extraction.

Serotonin Content Assay

Frozen tissue samples from the prefrontal cortex and
hippocampus were sonicated in 5 volumes of 0.IN HC1O4 and

centrifuged at 20000 g for 30 min at 4 °C. The supernatant
was then filtered through a 0.22 mm centrifugation unit at

2000 g for 5 min at 4 °C. Twenty microliters of the
resulting extracts were then assayed for 5-HT using high
performance liquid chromatography (582 pump and an MD-150
column; ESA, Chelmsford, MA) with electrochemical
detection (Coulochem II; ESA). The mobile phase consisted

of 75 mM NaH2PO4, 1.4 mM 1-octane sulfonic acid, 10 mM

EDTA, and 10% acetonitrile [(pH 3.1) MD-TM Mobile Phase;

ESA] and were pumped at a rate of 0.5 ml/min.
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Brain Derived Neurotrophic Factor Enzyme-Linked
Immunoassay
BDNF levels in the hippocampus and amygdala were
assessed using the Promega BDNF Emax Immunoassay System

(Promega, Madison, WI). Briefly, prefrontal, amygdala, and

hippocampal tissue were homongenized in distilled water
and sonicated for 15 s. Samples were then centrifuged at

16000 x g for 30 min and resulting supernantant collected.

Standard 96-well flat-bottom Corning ELISA plates were
incubated with carbonate coating buffer containing

monoclonal anti-BDNF overnight at 4°C. The next day, the
plates were blocked with lx TBST buffer for 1 hr at room
temperature. Serial dilutions of known amounts BDNF

ranging from 500 to 0 pg was performed in duplicate for
the standard curve for each rat sample. For both the

standards and the samples, 100 pl was added to each well

in duplicate and incubated 2 hr at room temperature. The
wells were then be incubated with a secondary anti-human
BDNF polyclonal antibody for 1 hr at room temperature.
Then, the wells were incubated with anti-IgY conjugated to
HRP for 1 hr at room temperature. A TMB solution was used

to develop color in the wells for 10 min at room
temperature. The reaction was stopped with the addition of
1 N HC1 to the wells.
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Statistical Design and Analysis

Two-way (drug * sex) analyses of variance (ANOVAs)
were used to analyze the data from elevated plus maze and

neurochemical (BDNF and monoamine content assay)
experiments. Tukey or Dunnett post hoc tests (p < 0.05)
were conducted as necessary. The independent variables for
all experiments was drug treatment (fluoxetine 10 mg/kg,

paroxetine 2.5 mg/kg, paroxetine 10 mg/kg, or vehicle)and
sex (male or female) The dependent variable, for the

elevated plus maze paradigm was number of entries and time

spent on the open arms. Separate statistical analyzes were
conducted for each of the three different brain regions

(hippocampus, amygdala, and .frontal cortex) used in the
neurochemical assays.
Baseline sucrose preference was analyzed by a 4 x 2 x

3 (drug x sex * test day) repeated measures ANOVA. Sucrose

preference after SSRI treatment was analyzed with a 4 * 2
(drug x sex) ANOVA. Side preference on the water

habituation day was analyzed by a (sex * side) repeated
measures ANOVA. Sucrose preference was defined using the

following formula:

[volume of sucrose ingested/ (the

volume of water ingested + volume sucrose ingested) x

100] .
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In order to control for litter effects, no more than
one subject from a litter was assigned to a particular

group. An equal number of male and female rats were
assigned to each group.
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CHAPTER SEVEN
RESULTS
Effects of Selective Serotonin Reuptake
Inhibitors on Body Weight

During the injection period (i.e., PD 35-44) male and

female rats exhibited a progressive increase in body

weight [day main effect, F(9,1107) = 686.922, p < 0.001]
(see Figure 1). This increase in body weight was altered
by SSRI treatment, sex and day [drug x day x sex

interaction, F(7,116) = 39.440, p < 0.001](see Figure 1).

Specifically, fluoxetine (10 mg/kg) significantly
decreased weight gain on PD 39-40 and PD 42-44 in female

rats and on PD 40-44 in male rats when compared to same
sex saline-treated controls [Tukey test, p < 0.05]. In

addition, paroxetine (10 mg/kg) significantly decreased

weight gain on PD 41-44, but only in male adolescent rats.
The lower dose of paroxetine did not significantly affect
the body weights of either male or female rats.
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Figure 1. Mean Body Weight in Grams (±SEM.) of Male

(n — 14-19) and Female (n = 13-16) Adolescent Rats Treated
with Vehicle, Paroxetine (2.5 or 10 mg/kg), or Fluoxetine
(10 mg/kg) from PD 35 to 44. *Indicates a Significant
Difference between Rats Treated with Fluoxetine (10 mg/kg)
and Rats Treated with Vehicle, flndicates a Significant

Difference in Male Rats Treated with Paroxetine (10 mg/kg)
Compared to Vehicle-Treated Male Rats
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Effects of Serotonin Reuptake Inhibitors
on Serotonin and 5HIAA Levels in the
Prefrontal Cortex and Hippocampus
Adolescent SSRI treatment altered the levels of

serotonin in the prefrontal cortex [drug main effect,
F(3,45) = 7.994, p < 0.001]

(see Figure 2). Chronic

treatment with both paroxetine (10 mg/kg) and fluoxetine
reduced serotonin levels when compared to vehicle-treated
controls [Tukey test, p < 0.05]. Levels of serotonin were
also reduced after paroxetine (10 mg/kg) treatment

compared to rats treated with paroxetine (2.5 mg/kg)
[Tukey test, p < 0.05]. Serotonin levels for rats treated

with paroxetine (2.5 mg/kg), however, did not differ from
saline-treated controls.

SSRI treatment also altered the levels of the primary
serotonin metabolite, 5HIAA, in the prefrontal cortex
[drug main effect F(3, 44) = 3.790, p < 0.05]. Fluoxetine

reduced 5HIAA levels when compared to both vehicle-treated
controls and rats given the lower dose of paroxetine (2.5

mg/kg)

[Tukey test, p < 0.05]. Similar to 5HIAA levels,

serotonin utilization or turnover (i.e., 5HIAA/5HT) was
also altered by SSRI treatment [drug main effect

F(3, 44) = 3.803, p < .05]

(Figure 3). Rats treated with

paroxetine (10 mg/kg) had greater serotonin turnover when
compared to fluoxetine-treated rats. However, neither the
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paroxetine- nor fluoxetine-treated groups differed
significantly from vehicle-treated rats.
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Figure 2. Mean Concentration of 5-HT (±SEM) in the
Prefrontal Cortex of Adolescent Male (n = 8) and Female

(n = 6-8) Rats 24 h after Last Drug Injection. Rats were

Treated with Vehicle, Paroxetine (2.5 or 10 mg/kg), or

Fluoxetine (10 mg/kg) from PD 35 to 44. Results are
Expressed in Picograms per Milligram (pg/mg) of Wet Weight

Tissue. ^Indicates a Significant Reduction Compared to
Vehicle-Treated Rats (p < 0.05)

51

Prefrontal Cortex

VEH

PAX10

PAX2.5

FLX10

Pretreatment Drug (mg/kg)
Figure 3. Mean Concentration of 5HIAA (±SEM) in the

Prefrontal Cortex of Adolescent Male (n = 8) and Female
(n = 6-8) Rats 24 h after Last Drug Injection. Rats were

Treated with Vehicle, Paroxetine (2.5 or 10 mg/kg), or

Fluoxetine (10 mg/kg) from PD 35 to 44. Results are
Expressed in Picograms per Milligram (pg/mg) of Wet Weight

Tissue. *Indicates a Significant Reduction Compared to

Vehicle-Treated Rats (p < 0.05)
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Prefrontal Cortex

Figure 4. Mean 5-HT Turnover (±SEM) in the Prefrontal

Cortex of Adolescent Male (n = 8) and Female (n = 6-8)

Rats 24 h after Last Drug Injection. Rats were Treated
with Vehicle, Paroxetine (2.5 or 10 mg/kg), or Fluoxetine

(10 mg/kg) from PD 35 to 44. Results are Expressed in
Picograms per Milligram (pg/mg) of Wet Weight Tissue.

^Indicates a Significant Increase Compared to VehicleTreated Rats (p < 0.05)

Serotonin levels in the hippocampus were decreased by
treatment with paroxetine (10 mg/kg) in both male and

female rats [drug treatment main effect, F(3,48) = 3.290,
p < 0.03, Tukey Test, p < 0.05]
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(see Figure 4).

Interestingly, the serotonin metabolite, 5HIAA, was
reduced by both paroxetine and fluoxetine treatment in a

sex-dependent manner [sex x drug treatment interaction,

F(3, 48) = 4.26, p < 0.01]. Specifically, female rats
showed decreased 5HIAA levels after both paroxetine

(10 mg/kg) and fluoxetine treatment while male rats only

showed a decrease after fluoxetine treatment [Tukey test,
p < 0.05]. Turnover of serotonin (i.e., 5HIAA/5HT) was

reduced after fluoxetine treatment [drug treatment main

effect, F(3, 48) = 6.403, p < 0.001, Tukey test, p < 0.05]
(Figure 5). The lower dose of paroxetine (2.5 mg/kg) did
not affect serotonin activity.
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&
the
I

Hippocampus of Adolescent Male (n = 8) and Female

(n = 6-8) Rats 24 h after Last Drug Injection. FLX10
Rats were
Treated with Vehicle, Paroxetine (2.5 or 10 mg/kg), or

Fluoxetine (10 mg/kg) from PD 35 to 44. Results are
Expressed in Picograms per Milligram (pg/mg) of Wet Weight

Tissue, indicates a Significant Reduction Compared to

Vehicle-Treated Rats (p < 0.05)
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Figure 6. Mean Concentration of 5HIAA (+SEM) in the

Hippocampus of Adolescent Male (n = 8) and Female

(n = 6-8) Rats 24 h after Last Drug Injection. Rats were
Treated with Vehicle, Paroxetine (2.5 or 10 mg/kg), or

Fluoxetine (10 mg/kg) from PD 35 to 44. Results are

Expressed in Picograms per Milligram (pg/mg) of Wet Weight
Tissue. *Indicates a Significant Reduction Compared to

Opposite Sex (p < 0.05)
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Figure 7. Mean 5-HT Turnover (+SEM) in the Hippocampus of

Adolescent Male (n = 8) and Female (n = 6-8) Rats 24 h
after Last Drug Injection. Rats were Treated with Vehicle,

Paroxetine (2.5 or 10 mg/kg), or Fluoxetine (10 mg/kg)
from PD 35 to 44. Results are Expressed in Picograms per
Milligram (pg/mg) of Wet Weight Tissue. *Indicates a

Significant Reduction Compared to Vehicle-Treated Rats
(p < 0.05)

Effects of Serotonin Reuptake Inhibitors on Brain
Derived Neurotrophic Factor Levels in the
Hippocampus and Amgydala
Hippocampal BDNF levels were altered by SSRI

treatment in a sex-dependent fashion [sex x drug treatment
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interaction, F(3, 39) - 3.782, p < 0.02]

(see Figure 6).

In female rats, BDNF levels were increased by fluoxetine
treatment, while male rats were unaffected [Dunnett test,

p < 0.05]. In contrast, paroxetine treatment decreased

BDNF levels in male rats, with no effect on the BDNF

levels of female rats [Dunnett test, p < 0.05]. There was
no significant difference in BDNF levels in the amygdala
after repeated SSRI treatment.
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Hippocampus

Pretreatment Drug (mg/kg)
Figure 8. Mean Brain Derived Neurotropic Factor Protein'
Content (±SEM) in the Hippocampus of Adolescent Male

(n = 6-7) and Female (n = 5-6) Rats 24 h after Last Drug
Injection. Rats were Treated with Vehicle, Paroxetine (2.5

or 10 mg/kg), or Fluoxetine (10 mg/kg) from PD 35 to 44.

Results are Expressed in Nanograms per Milligram (ng/mg)
Protein. *Indicates a Significant Difference from Same Sex

Vehicle-Treated Rats (p < 0.05)

Effects of Serotonin Reuptake Inhibitors
on Sucrose Preference

On the water habituation day (i.e., first day of
training), male rats (M = 23.836 g, SEM ± 0.40) drank more
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water than female rats (M = 21.034 g, SEM ± 0.38)

[sex main

effect, F(l, 62) = 26.152, p < 0.001]. Moreover, both male
and female rats drank more water from the right side

(M = 12.768 g, SEM ± 0.58) than the left side (M = 9.579 g,
SEM ±0.51) on the water habituation day [side main effect,

F(l, 62) = 9.566, p < 0.005. Before SSRI treatment there was
no difference between male and female rats in the total
amount of water or sucrose consumed. There was also no
difference in preference scores over the three baseline

preference days. Total sucrose consumption was greater for
both male and female rats on Baseline day 1 (M = 35.515 g,
SEM ± 2.44) than on Baseline Days 2 and 3 (M = 30.752 g,
SEM ± 2.46; M = 31.831 g, SEM ± 2.54, respectively). After

10 days of SSRI treatment, there was no difference in total
water or sucrose consumed when measured on the final test

day. In addition, a Pre/Post preference score (Final

preference score - Average of 3 baseline preference scores)

showed that the drug treatment did not affect sucrose
preference. However, the total amount of sucrose consumed
was affected by SSRI treatment, because rats treated with

the lower dose of paroxetine (2.5 mg/kg) consumed greater

levels of sucrose when compared to rats that received the
higher dose of paroxetine (10 mg/kg) or fluoxetine (10

mg/kg)

[drug treatment main effect F(3, 46) = 3.286,
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p < 0.03, Tukey Test, p < 0.05]

(see Table 1). However, none

of the drug treatment groups differed significantly from the
vehicle-treated rats.

Table 1. Effects of Selective Serotonin Reuptake Inhibitor

Treatment on Sucrose Consumption, Water Consumption and

Sucrose Preference in Adolescent Male and Female Rats.

Rats were Treated with Vehicle, Paroxetine (2.5 or 10
mg/kg), or Fluoxetine (10 mg/kg) from PD 35 to 44.
verage
Post-Exposure
Pre/Post
____Pre Exposure________________________ Preference
Score
Water
Sucrose
Water
Sucrose

Male
Vehicle

33.12
(±3.5)

1.87
(±0.4)

38.31
(±5.8)

6.19
(±2.7)

0.88
(±0.1)

Paroxetine
(2.5 mg/kg)

36.64
(±5.0)

3.38
(±1.6)

48.41
(±10.7)

3.72
(±1.4)

1.03
(±0.1)

Paroxetine
(10 mg/kg)

26.59
(±5.1)

5.13
(±3.4)

33.25
(±7.0)

6.38
(±3.6)

1.09
(±0.1)

Fluoxetine
(10 mg/kg)

26.11
(±5.3)

6.81
(±2.7)

33.44
(±7.1)

10.08
(±4.1)

0.99
(±0.2)

Vehicle

33.13
(±8.6)

4.93
(±1.5)

50.44
(±13.0)

4.88
(±2.4)

1.00
(±0.1)

Paroxetine
(2.5 mg/kg)

31.35
(±8.0)

6.87
(±2.6)

63.45*
(±15.5)

3.09
(±0.80)

2. 84
(±1 .7)

Paroxetine
(10 mg/kg)

32.13
(±5.2)

4.71
(±1.8)

36.45
(±9.4)

5.75
(±2.3)

0. 93
(±0 .0)

Fluoxetine

29.67

5.73

34.54

4.62

1. 12

Female
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(10 mg/kg)

(+6.5)

(±2.7)

(±5.7)

(±2.7)

(±0.1)

indicates a significant difference from rats treated with 10
mg/kg paroxetine or 10 mg/kg fluoxetine (p < 0.05).

Effects of Serotonin Reuptake Inhibitors
treatment on Elevated Plus Maze Behavior

There was no effect of sex or drug treatment on any
of the measures assessed on the elevated plus maze during
the 5 min testing period (see Table 2).

Table 2. Effects of Selective Serotonin Reuptake Inhibitor

Treatment on Elevated Plus Maze Behavior of Adolescent

Male and Female Rats. Rats were Treated with Vehicle,

Paroxetine (2.5 or 10 mg/kg), or Fluoxetine (10 mg/kg)
from PD 35 to 44.
Duration Duration
in closed in open Ratio
arms (s)
arms(s)

Closed
arm
entries

Open arm
Ratio
entries

Male
Vehicle

Paroxetine
(2.5 mg/kg)
Paroxetine
(10 mg/kg)
Fluoxetine
(10 mg/kg)
Female
Vehicle

Paroxetine
(2.5 mg/kg)

139.49
(±9.8)
137.09
(±20.1)
126.15
(±12.0)
137.26
(±9.0)

57.98
(±10.0)
66.02
(±15.0)
91.55
(±7.8)
64.85
(±9.3)

131.50
(±11.4)
141.71
(±13.3)

73.70
(±11.0)
63.66
(±10.5)

10.25
(±1.2)
10.25
(±0.5)
10.29
(±0.8)
10.38
(±1.0)

5.13
(±0.9)
6.75
(±1.6)
6.86
(±1.7)
5.63
(±0.7)

0.56

10.57
(±1.2)

0.45

10.56
(±1.3)

6.71
(±0.8)
5.78
(±1.0)

0.42
0.48

0.73
0.47
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0.50

0.66
0.67
0.54

0.64

0.55

Paroxetine
(10 mg/kg)
Fluoxetine
(10 mg/kg)

124.07
(±12.2)
123.98
(±9.6)

80.63
(±12.4)
79.91
(±11.3)

0.65
0.64

63

10.38
(±1.5)
10.88
(±1.2)

6.13
(±0.6)
6.88
(±1.1)

0.59
0.63

CHAPTER EIGHT

DISCUSSION
Introduction
Fluoxetine and paroxetine are commonly prescribed for
the treatment of major depressive disorder in pediatric

populations. In this population, paroxetine is not

efficacious and has been shown to increase rates of
suicidal behavior (Emslie et al., 2006; Tiihonen,

Lonngvisy, Wahlbeck, Klaukka, Tanskanen, & Haukka, 2006).

In contrast, fluoxetine is an effective treatment for

depression in adolescence and adulthood and has a much
lower risk for inducing suicidal behavior (Ipser, Stein,
Hawkridge, & Hoppe, 2009; Lovrin, 2009; Masi, Liboni, &

Borovedani, 2010). The reason for the paradoxical increase
in suicidal behavior in pediatric populations is unknown
but may be the result of age-dependent differences in the

neuronal response to paroxetine. Thus, the goal of the

present investigation was to compare the effects of
paroxetine and fluoxetine in adolescent rats using
neurochemical and behavioral markers associated with

depression and suicide in humans. Our results revealed

that 10 consecutive days of SSRI administration was
sufficient to cause changes in neuronal activity.
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Specifically, paroxetine treatment caused a significant
reduction in serotonin concentrations in both the

prefrontal cortex and hippocampus, while fluoxetine only
reduced serotonin levels in the prefrontal cortex.

Paroxetine also caused a reduction in BDNF levels in the
hippocampus, while fluoxetine increased BDNF levels. These

antidepressants, however, only caused minor alterations on
depression- and anxiety-related behavioral tasks, because
neither elevated plus maze behavior or sucrose preference
was altered after SSRI treatment.

Effects of Selective Serotonin Reuptake
Inhibitors on Body Weight
Consistent with both human and rodent studies,

fluoxetine treatment led to significantly reduced body
weight in both male and female adolescent rats (de Jong et

al., 2006; Konkle & Bielajew, 1999, Mancini & Halpern,
2006; McNamara, Able, Rider, Tso, & Jandacek, 2010;
Mitchell, De Zwaan, & Roerig, 2003; Ward, Comer, Haney,

Fischman, & Foltin, 1999). This result may be explained by

multiple factors including increased activation of 5-HTX/2
receptors and the increased synaptic availability of
serotonin causing appetite suppression (Halford, Harrold,

Boyland, Lawton, & Blundell, 2007; Simansky, 1996).

65

Interestingly, chronic treatment with paroxetine
(10 mg/kg) significantly reduced weight gain in adolescent
males but not females. This indicates that there is a
sex-specific difference between the two SSRIs in their

effect on the serotonergic activity associated with weight

gain. The ability of fluoxetine and paroxetine as

anorectic agents is not correlated with their potency as
serotonin reuptake inhibitors, because fluoxetine is less

potent than paroxetine in blocking serotonin reuptake.
This indicates that the anorectic effect of SSRIs may be

mediated by other mechanisms. Lastly, the lower dose of

paroxetine (2.5 mg/kg) did not affect weight gain in
either sex, consistent with other studies (Konkle &

Bielajew, 1999).

Neurochemical Markers of Depression and Suicide

The present results confirm and extend previous
research demonstrating that chronic fluoxetine

administration can significantly decrease serotonin and
5HIAA levels in adolescent prefrontal cortex (Caccia,

Fracasso, Garattini, Guiso, & Sarati, 1992; Fuller,

Snoddy, & Robertson, 1988). Serotonin concentrations in
the prefrontal cortex were reduced after paroxetine

(10 mg/kg) treatment to levels that are similar to
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fluoxetine-treated rats. Moreover, fluoxetine treatment

caused an overall reduction in cortical 5HIAA, whereas
paroxetine (2.5 or 10 mg/kg) was without significant
effect. This suggests that while serotonin levels are

reduced after paroxetine administration, the metabolism of

serotonin remains unaffected. Levels of hippocampal
serotonin were reduced only by the higher dose of
paroxetine (10 mg/kg). Serotonin levels were not affected

by chronic fluoxetine treatment in the hippocampus;
however, serotonin turnover was significantly reduced.
Interestingly, hippocampal 5HIAA levels were altered by
the SSRIs in a sex-dependent manner. 5HIAA levels were

reduced in females treated with paroxetine (10 mg/kg) or
fluoxetine, but only males rats treated with fluoxetine

exhibited reductions in hippocampal 5HIAA. The mechanism

by which administration of SSRIs reduce serotonin content
is unknown. It is possible, however, that this decrease in

serotonin content was due to either (a) increased
sensitivity of the serotonin autoreceptors or (b) down

stream feedback mechanisms.
Repeated SSRI treatment caused a significant
sex-dependent effect on BDNF concentrations in the

hippocampus. Fluoxetine (10 mg/kg) treatment in female

rats significantly increased the concentration of BDNF,
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while paroxetine (10 mg/kg) significantly decreased BDNF

concentration in males. The ability of fluoxetine to
increase BDNF in adolescent females mimics the results
found in adult females given a similar dose (Hodes, Yang,
Van Kooy, Santollo, & Shors, 2010) . Moreover, the finding

that fluoxetine did not alter BDNF levels in adolescent

males, is in agreement with studies done in adult males
(Alter, Whitehead, Chen, Wortwein & Madsen, 2003; De
Foubert et al., 2004). Currently, the only available data

on BDNF activity after SSRI treatment in adolescence is
indirect, because cell proliferation was measured and not

BDNF levels. Cell proliferation is an expression of
neurogenesis, which is mediated by BDNF protein. In

adolescent rats, fluoxetine exposure has no effect on cell

proliferation (Cowen et al., 2008; Hodes, Yang, Van Kooy,

Santollo, & Shor, 2009).

To our knowledge, the effects of paroxetine on BDNF
levels in adolescents have not been previously

investigated. In the present study, we found a reduction

in BDNF after paroxetine exposure in males. Adult studies
have demonstrated an increase in BDNF gene expression
after repeated treatment of paroxetine (Coppell, Pei, &

Zetterstrom, 2003). However, Coppell et al.

(2003) used a

longer administration regimen, which may have resulted in
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a heightened BDNF response. Increases in BDNF
concentrations may not directly elevate mood, but rather

enhance BDNF signaling in mood-regulating circuits
(Castren, 2005; Groves, 2007). Further research is
necessary to elucidate the mechanism by which repeated

SSRI treatment affects neurogenesis.
Behavioral Markers of Depression and Suicide
Overall, paroxetine and fluoxetine did not have a
robust effect on behavioral measures associated with
depression- and suicide-related behaviors. For example,

sucrose consumption and preference, measures of hedonia in
animals, were not affected by SSRI treatment. However,

sucrose consumption was significantly increased in female

rats after chronic administration of paroxetine
(2.5 mg/kg) when compared to paroxetine (10 mg/kg) and

fluoxetine (10 mg/kg) treatment in female rats. In males,
chronic fluoxetine treatment during adolescence can cause
slight increases in sucrose preference at very low sucrose
concentrations

(Iniguez, Warren, & Bolanos-Guzman, 2010).

This finding implies that administering SSRIs during

adolescence may minimally alter sensitivity to natural
reward.
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It is important to note that both paroxetine and

fluoxetine treatment can induce nausea (Limebeer, Litt, &

Parker, 2009; Tuerke, Leri, & Parker, 2009). However, the
doses used in our study have not been shown to induce a

significant increase in aversive taste reactivity.

Moreover, SSRIs have been shown to reduce caloric intake
and the palatability of sweet solutions (Asin, Davis, &

Bednarz, 1992; Halford & Blundell, 2000; Halford, Harrold,

Lawton, & Blundell, 2005; Simansky & Eberle-Wang, 1993).

However, our study did not show an effect of SSRI
administration on consumption of sucrose. Overall, it does
not appear that sucrose intake was affected by a reduction

in weight or an aversive gustatory response.
Neither chronic administration of paroxetine or

fluoxetine changed the behavior of adolescent rats on the
elevated plus maze. There was a trend for male rats

treated with paroxetine (10 mg/kg) to spend a greater

duration of time in the open arms of the plus maze,
however this effect was not significant. High variability
between litters may have lead to these non-signifleant
findings, although the few studies examining anxiety-like
behavior after fluoxetine treatment have provided

conflicting results (Iniguez et al., 2010;' Norcross et

al., 2008; Oh, Zupan, Gross, & Toth, 2009). Iniguez et al.
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(2010) and Oh et al.

(2009) both found a decrease in

entries and duration on the open arms of the elevated plus
maze after long-term fluoxetine treatment. In contrast,
Norcross et al.

(2008) found no significant effects of

fluoxetine treatment in this paradigm. The only study
examining anxiety-like behavior after paroxetine treatment

found a decrease in the time spent in the open arms (de
Jong et al., 2006).
Sex-Differences in Markers of
Depression and Suicide

To our knowledge, there is no published data on the

behavioral effects of SSRI administration in adolescent
females. Moreover, the studies conducted in adolescent

male rats have produced mixed results. Overall, it seems
that SSRIs do not affect or increase depression- and
anxiety-like behaviors in adolescent rats (Olivier, Blom,

Arentsen, & Homberg, 2010) . In the present study, SSRI
treatment did not affect the elevated plus maze

performance of either male or female rats. The drugs had
only a minimal effect on sucrose preference. The
inconclusive results reported here and discrepancies in

past research should provide further impetus to

investigate the effects of SSRIs on adolescent behavior.
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Only marginal sex differences in neurochemistry were
induced by SSRI treatment. Sex differences in the

serotonergic system of the prefrontal cortex tend to
develop during puberty, which occurs around the fifth to

sixth postnatal week (Ojeda & Urbanski, 1994). In the
current study, SSRI treatment ended at the beginning of
this stage of development. Therefore, the potential effect

of sex-dependent hormones cannot be ignored. A sex
dependent effect was found in BDNF levels. Males did not
show a significant response to fluoxetine treatment, while

female rats had a dramatic increase in BDNF levels.
Similarly, Hodes et al.

(2009) demonstrated that

fluoxetine increased hippocampal neurogenesis in females

when compared to age-matched males. Fluoxetine treatment
can significantly affect the regulation and the maturation

of estrus cycling in rats (Amsterdam et al., 1997; Hodes
et al., 2010; Maswood, Sarkar, & Uphouse, 2008). In
particular, gonadal hormones can affect hippocampal
neurogenesis (mediated by BDNF), possibly contributing to
the observed sex differences in cell survival (Galea,

2008). Sex differences may also be due to variations in
the metabolism of antidepressants. Compared to males,

female rats sustain a higher level of norfluoxetine, the

major active metabolite of fluoxetine (Ferguson & Hill,
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2006). Higher circulating levels of norfluoxetine in
females may increase serotonin levels for a longer period

(Hodes et al., 2009). Thus, the pharmacokinetics of these

SSRIs may play a role in the neurochemical differences
between sexes (Hodes et al., 2010).
Conclusion
Caution is necessary when translating rodent data to
humans, because there are important differences in

metabolism, development, and hormones. However, there are

many commonalities between suicidal adolescent humans and
rats that exhibit behaviors associated with suicide. For

example, in adolescent humans, plasma serotonin levels are

negatively correlated with suicidal and violent behavior
(Tyano et al., 2006), while 5HIAA levels are negatively
correlated with aggression (Kruesi et al., 1990).

Postmortem studies in adolescent humans have demonstrated
an up-regulation of 5-HT2A receptors and mRNA in the

hippocampus and prefrontal cortex of suicide completers

(Pandey et al., 2002). This indicates a reduction in

serotonin availability in these particular brain regions.
A similar pattern emerges in rodent studies using

analogous age groups. Low levels of serotonin and
serotonin turnover are correlated with high levels of
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aggression (Eichelman & Thoa, 1973; Gibbons, Barr,
Bridger,

& Leibowitz, 1979; Miyachi, Kasai, Ohyama, &

Yamada, 1994; Valzelli, 1973), as well as disinhibited
behavior (Pothakos, Robinson, Gravanis, Marsteller, Dewey,

& Tsirka, 2009). Results from the current study showed a
decrease in serotonin after both SSRI treatments, but only

fluoxetine reduced serotonin turnover. The current results
suggest that short-term administration of paroxetine and

fluoxetine may decrease serotonin activity in a manner
similar to humans who exhibit suicidal behavior.

BDNF levels in depressed patients are negatively

correlated with the severity of depression and suicidal
behavior (Yoshimura et al., 2007). Furthermore,
antidepressant treatment can increase BDNF levels in
depressed patients (Aydemir, Deveci, & Taneli, 2005;

Aydemir et al., 2006; Gervasoni et al., 2005; Gonul,

Akdeniz, Taneli, Donat, Eker, & Vahip, 2005; Karege,
Perret, Bondolfi, Schwald, Bertschy, & Aubry, 2002;

Karege, Schwald, & Cisse, 2002; Shimizu et al., 2003).
This human research suggests that BDNF levels may be a

biological marker of suicidal depression (Yoshimura et

al., 2007). Animal studies parallel these findings,

demonstrating that reduced hippocampal BDNF levels can
cause depressive-like behavior, while repeated
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antidepressant treatment can cause neurogenesis by

increasing BDNF (Wang, David, Monckton, Battaglia, & Hen,

2008). The present study found an increase in BDNF after

fluoxetine treatment in females, which may imply that
fluoxetine has a beneficial sex-specific effect during
adolescence. Paroxetine on the other hand, caused no
beneficial effect in females and had a negative

consequence (e.g., decreased BDNF levels) in adolescent

male rats. Administering paroxetine to adult humans

affects BDNF levels in an inconsistent manner (Lee, Myint,
& Kim, 2010); however, the majority of research shows that
paroxetine exposure increases BDNF expression (Gonul et

al., 2005; Hellweg, Ziegernorn, Heuser, & Deuschle, 2008;

Yoshimura et al., 2007).
An important caveat is that these experiments were
conducted using normal (i.e., non-depressed) rats. In

other words, it is possible that our neurochemical results

are not reflective of what would be observed using a

"depressed" rat. However, a number of recent studies
suggest that normal and "depressed" male rats respond

similarly to SSRIs. Specifically, repeated SSRI treatment
affects the brain neurochemistry, including BDNF
expression, of non-stressed and stressed rats in a similar

manner (chronic stress is a well-characterized rodent
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model of depression)

(Qi, Lin, Li, Wang, Wang, & Sun,

2008; Schulte-Herbruggen, Fuchs, Ziegler, Danker-Hopfe,
Hiemke, & Hellweg, 2009.

In summary, the current investigation showed that
paroxetine administration during adolescence caused
detrimental effects on neural mechanisms associated with
suicidal and depressive behaviors. Importantly, the SSRI-

induced changes in serotonin and BDNF did not affect

depressive-like behavior as expected. The failure to find
changes in our behavioral markers may have occurred

because (a) the drug treatment did not extend long enough

or (b) we did not wait long enough after conclusion of the
drug regimen for the behavioral changes to manifest. While

our work is preliminary, these data suggest that
paroxetine may induce suicidal ideation and behavior by
decreasing both serotonin and BDNF levels.
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